Vivos (VVOS) falls 2.35% on Moderate Volume January 14

Equities Staff  |

Vivos Therapeutics Inc (NASDAQ: VVOS) fell to close at $1.87 Friday after losing $0.045 (2.35%) on volume of 50,124 shares. The stock ranged from a high of $1.94 to a low of $1.85 while Vivos’s market cap now stands at $43,032,663.

About Vivos Therapeutics Inc

Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Combining technologies and protocols that alter the size, shape and position of the tissues of the upper human airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. Sales of the Vivos System are driven by the Vivos Integrated Practice (VIP) program, which offers dentists training and value-added services in connection with their use of the Vivos System.

Visit Vivos Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Vivos Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Vivos Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Commodities Post Strongest Gains in Over a Decade
Charlie Munger Doubles Down on Alibaba While the Fed Signals Tightening
Commodities — Assessing 2021 and Forecasting 2022



Market Movers

Sponsored Financial Content